New number of shares and votes in Swedish Orphan Biovitrum AB (publ)

The total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi) as per
29 November 2013 amounts to 270,389,770 shares, all common shares, corresponding
to in total 270,389,770 votes. The increase in the number of common shares and
votes results from a conversion of all 5,163,172 class C shares held by the
company into common shares. The shares are intended to ensure fulfillment of
commitments under incentive programs.

---


About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on inflammation and genetic diseases, with three late stage biological
development projects within haemophilia and neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi is
a pioneer in biotechnology with world-class capabilities in protein biochemistry
and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion
(€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com

For more information - not for publication
Media relations           Investor relations

Oskar Bosson, Head of     Jörgen
Communications            Winroth, Vice President, Head of Investor Relations

T: +46 70 410 71 80       T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135

oskar.bosson@sobi.com     jorgen.winroth@sobi.com



The above information has been made public in accordance with the Financial
Instruments Trading Act. The information was released for public distribution on
29 November 2013 at 08:00 CET.

[HUG#1746473]